1. (2) In these Rules, a reference to a request to an approved pathology practitioner includes a reference to a request for a pathologist-determinable service to which subsection 16A (6) of the Act applies.

1. (3) A reference in this Table by number to an item that is not included in this Table is a reference to the item that has that number in the general medical services table or the diagnostic imaging services table, as the case requires.

1. (4) A reference to a Group in the Table includes every item in that Group.

Certain pathology services to be treated as one service

1A. (1) In this rule:

“general practitioner” means a medical practitioner who:

(a) is not a consultant physician in any specialty; and

(b) is not a specialist in any specialty;

“set of pathology services” means a group of pathology services:

(a) that consists of services that are described in at least 4 different items; and

(b) all of which are requested in a single patient episode; and

(d) none of which is referred to:

(i) in item 66241, 66417, 69241, 73053 or 73055; or

(ii) in an item in Group P10 (Patient episode initiation) or Group P11 (Specimen referred).

1A. (2) If a general practitioner requests a set of pathology services, the pathology services in the set are to be treated as individual pathology services in accordance with this rule.

1A. (3) If the fee specified in one item that describes any of the services in the set of pathology services is higher than the fees specified in the other items that describe the services in the set:

(a) the pathology service described in the first-mentioned item is to be treated as one pathology service; and

(b) either:

(i) the pathology service in the set that is described in the item that specifies the second-highest fee is to be treated as one pathology service; or

(ii) if 2 or more items that describe any of those services specify the second-highest fee—the pathology service described in the item that specifies the second-highest fee, and that has the lowest item number, is to be treated as one pathology service; and

(c) the pathology services in the set, other than the services that are to be treated as one pathology service under paragraphs (a) and (b), are to be treated as one pathology service.

1A. (4) If the fees specified in 2 or more items that describe any of the services in the set of pathology services are the same, and higher than the fees specified in the other items that describe the services in the set:

(a) the pathology service in the set that is described in the item that specifies the highest fee, and that has the lowest item number, is to be treated as one pathology service; and

(b) the pathology service in the set that is described in the item that specifies the highest fee, and that has the second-lowest item number, is to be treated as one pathology service; and

(c) the pathology services in the set, other than the services that are to be treated as one pathology service under paragraphs (a) and (b), are to be treated as one pathology service.

1A. (5) If pathology services are to be treated as one pathology service under paragraph 1A (3) (c) or paragraph 1A (4) (c), the fee for the one pathology service is the highest fee specified in any of the items that describe the pathology services that are to be treated as the one pathology service.

Precedence of items

2. (1) If a service is described:

(a) in an item in general terms; and

(b) in another item in specific terms;

only the item that describes the service in specific terms applies to the service.

2. (2) Subject to subrule (3), if:

(a) subrule (1) does not apply; and

(b) a service is described in 2 or more items;

only the item that provides the lower or lowest fee for the service applies to the service.

2. (3) If an item is expressed to include a pathology service that is described in another item, the other item does not apply to the service in addition to the first-mentioned item, whether or not the services described in the 2 items are requested separately.

Circumstances in which services rendered following 2 requests to be taken to have been rendered following 1 request

3. (1) In subrule 3 (2), “service” includes assay, estimation and test.

3. (2) Two or more pathology services (other than services to which, under rule 4, this rule does not apply) rendered for a patient following 2 or more requests are taken to have been rendered following a single request if:

(a) the services are listed in the same item; and

(b) the patient’s need for the services was determined under subsection 16A (1) of the Act on the same day even if the services are rendered by an approved pathology practitioner on more than one day.

Services to which rule 3 does not apply

4. (1) Rule 3 does not apply to:

(a) a pathology service described in item 66201, other than an estimation of fructosamine or lithium; or

(b) quantitative estimation, described in item 66365, of 1 or more fractions of neonatal bilirubin;

if:

(c) the service is rendered in relation to a single specimen taken on each of not more than 4 occasions in a period of 24 hours; and

(d) the service is rendered to a patient in a hospital unit where:

(i) the presence of 1 nurse is required for each group of not more than 4 patients; and

(ii) the condition of the patients is continuously observed in relevant respects; and

(e) in order to render the service, an approved pathology practitioner who is a recognised pathologist has to arrange for a member of the laboratory staff of the approved pathology authority concerned to undertake duties in respect of the service that are in addition to the usual duties of the staff member; and

(f) the account for the service is endorsed “Rule 3 Exemption”.

4. (2) Rule 3 does not apply to any of the following pathology services:

(a) estimation of prothrombin time in respect of a patient undergoing anticoagulant therapy;

(b) quantitative estimation of lithium in respect of a patient undergoing lithium therapy;

(c) a service described in item 65007 in relation to a patient undergoing chemotherapy for neoplastic disease or immunosuppressant therapy;

(d) a service described in item 65007 in relation to methotrexate, gold sulfasalazine or penicillamine therapy of a patient;

(e) a service described in item 66201 in relation to methotrexate therapy of a patient;

(f) quantitative estimation of urea, creatinine and electrolytes in relation to:

(i) cis-platinum therapy of a patient; or

(ii) chronic renal failure of a patient being treated in a dialysis program conducted by a recognised hospital;

if:

(g) under a request for a service, no more than 6 tests are requested; and

(h) the tests are performed within 6 months of the request; and

(i) the account for the service is endorsed “Rule 3 Exemption”.

4. (3) Rule 3 does not apply to a pathology service:

(a) to which item 66221 applies; and

(b) for which a specimen is collected on each of 3 days for the purpose of making a valid estimation; and

Item taken to refer only to the first service of a particular kind

5. For the purposes of an item in Group P1 (Haematology):

(a) if pathology services of a kind referred to in item 65017 or 65019 are rendered for a patient during a period when the patient is in hospital, the item applies only to the first pathology service of that kind rendered for the patient during that period; and

(b) if:

(i) tests (except tests mentioned in item 65023) are carried out in relation to a patient episode; and

(ii) specimen material from the patient episode is stored; and

(iii) in response to a request made within 14 days of the patient episode, further tests (except tests mentioned in item 65023) are carried out on the stored material;

the later tests and the earlier tests are taken to be part of one patient episode.

Certain items not to apply to a service referred by one pathology practitioner to another

6. (1) In this rule:

“designated pathology service” means a pathology service in respect of tests relating to a single patient episode that are:

(a) tests of the kind described in item 66235; or

(b) tests of the kind described in item 66405; or

6. (2) This rule applies in respect of a designated pathology service where:

(a) an approved pathology practitioner (“practitioner A”) in an approved pathology authority:

(i) has been requested to render the designated pathology service; and

(ii) is unable, because of the lack of facilities in, or expertise or experience of the staff of, the laboratory of the authority, to render 1 or more (but not all) of the tests included in the service; and

(iii) requests an approved pathology practitioner (“practitioner B”) in another approved pathology authority to render the test or tests that practitioner A is unable to render; and

(iv) renders each test included in the service, other than the test or tests in respect of which the request mentioned in subparagraph (iii) is made; and

(b) the tests mentioned in subparagraph (a) (iv) that practitioner A renders are not tests constituting a service described in item 66239, 66415 or 69239.

6. (2A) Where this rule applies in respect of a designated pathology service:

(a) item 66235, 66237, 66405, 66407, 66409, 66411, 66413, 69229, 69231, 69233, 69235 or 69237 (as the case requires) applies in respect of the test or tests rendered by practitioner A; and

(b) where practitioner B renders a service under a request referred to in subparagraph (2) (a) (iii)—subject to subrule (2B), the amount specified in item 66241, 66417 or 69241 (as the case requires) is payable for each test that the service comprises.

6. (2B) For the purposes of paragraph (2A) (b), the maximum number of tests to which item 66241, 66417 or 69241 applies is:

(a) in the case of item 66241:

3 - X; or

(b) in the case of item 66417 or 69241:

6 - X;

where “X” is the number of tests rendered by practitioner A in relation to the designated pathology service in respect of which the request mentioned in that paragraph is made.

6. (3) Items in Group P10 (Patient episode initiation) do not apply to the second-mentioned approved pathology practitioner in subrule (2).

Items not to be split

6A. Except as stated in rule 6, the amount specified in an item is payable only to one approved pathology practitioner in respect of a single patient episode.

Certain tests on stored material to be treated as part of the same patient episode

7. For the purposes of items in Group P2 (Chemical):

(a) if a pathology service that involves the measurement of a substance in urine requires calculation of a substance/creatinine ratio, the service is taken to include the measurement of creatinine necessary for the calculation; and

(b) if:

(i) tests are carried out in relation to a patient episode; and

(ii) specimen material from the patient episode is stored; and

(iii) in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material;

the later tests and the earlier tests are taken to be part of one patient episode.

Item 66317

7A. The amount specified in item 66317 is not payable in respect of a pathology service described in the item unless at least one of the following paragraphs applies:

(a) if the HDL cholesterol or apolipoprotein B/A1 ratio of the patient is requested to be determined because the patient has a serum cholesterol level >5.5 mmol/1—the determination is performed on the sample that the serum cholesterol level determination for the patient was performed;

(b) if the HDL cholesterol or apolipoprotein B/A1 ratio of the patient is requested to be determined because the patient has a fasting serum triglyceride level >2.0 mmol/1—the determination is performed on the sample that the serum triglyceride level determination for the patient was performed;

(c) the pathologist who renders the service has a written statement from the medical practitioner who requested the service that the patient is on a lipid lowering drug.

Thyroid function testing

7B. (1) For the purposes of item 66329:

“abnormal level of TSH” means a level of TSH that is outside the normal reference range in respect of the particular method of assay used to determine the level.

7B. (2) Except where paragraph (a) of item 66329 is satisfied, the amount specified in the item is not payable in respect of a pathology service described in the item unless the pathologist who renders the service has a written statement from the medical practitioner who requested the service that satisfies subrule (3).

7B. (3) The written statement from the medical practitioner must indicate:

(a) that the tests are required for a particular purpose, being a purpose specified in paragraph (b) of item 66329; or

(b) that the medical practitioner who requested the tests suspects the patient has pituitary dysfunction; or

Meaning of “serial examinations or cultures”

8. For the purposes of an item in Group P3 (Microbiology):

(a) “serial examinations or cultures” means a series of examinations or cultures requested on 1 occasion whether or not:

(i) the materials are received on different days by the approved pathology practitioner; or

(ii) the examinations or cultures were requested on 1 or more request forms by the treating practitioner; and

(b) if:

(i) tests are carried out in relation to a patient episode; and

(ii) specimen material from the patient episode is stored; and

(iii) in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material;

the later tests and the earlier tests are taken to be part of one patient episode.

Tests in Group P4 (Immunology) relating to antibodies

9. For the purposes of items in Group P4 (Immunology), in items 71119, 71121, 71123 and 71125, if:

(a) tests are carried out in relation to a patient episode; and

(b) specimen material from the patient episode is stored; and

(c) in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material;

the later tests and the earlier tests are taken to be part of one patient episode.

Tests on biopsy material—Group P5 (Tissue Pathology) and Group P6 (Cytology)

10. (1) For the purposes of items in Group P5 (Tissue Pathology):

(a) “biopsy material” means all tissue (other than a bone marrow biopsy) received by an approved pathology practitioner from an operation, or a group of operations, performed on a patient at the same time; and

(b) if:

(i) a pathology service that comprises the examination of biopsy material is rendered under any of those items; and

(ii) a further pathology service mentioned in any of those items is also rendered using that biopsy material;

those pathology services are taken to be 1 pathology service; and

(c) “cytology” means microscopic examination of 1 or more stained preparations of cells separated naturally or artificially from their normal environment by methods recognised as adequate to demonstrate their structure to a degree sufficient to enable an opinion to be formed about whether they are likely to be normal, abnormal but benign, or abnormal and malignant. In accordance with customary laboratory practice examination of a blood film and a bone marrow aspirate is excluded from this definition.

10. (2) For the purposes of Groups P5 and P6 of the Pathology Services Table, services in Group P6 include any services described in Group P5 on the material submitted for a test in Group P6.

10. (3) For the purposes of subrule 10. (2), any sample submitted for cytology from which a cell block is prepared does not qualify for a Group P5 item.

Items in Groups P10 (Patient episode initiation) and P11 (Specimen referred) not to apply in certain circumstances

11. (1) For the purposes of this rule and items in Groups P10 (Patient episode initiation) and P11 (Specimen referred):

“institution” means a place at which residential accommodation or day care is, or both residential accommodation and day care are, made available to:

(a) disadvantaged children; or

(b) juvenile offenders; or

(d) chronically ill psychiatric patients; or

(e) homeless persons; or

(f) unemployed persons; or

(g) persons suffering from alcoholism; or

(h) persons addicted to drugs; or

(i) physically or mentally handicapped persons;

but does not include:

(j) a hospital; or

(k) a nursing home; or

(l) accommodation for aged persons that is attached to a nursing home or situated within a nursing home complex;

“licensed collection centre” has the same meaning as in Part IIa of the Act;

“prescribed laboratory” means a laboratory operated by:

(a) the Commonwealth; or

(b) a State or internal Territory; or

(d) an Australian tertiary education institution;

“specimen collection centre” has the same meaning as in Part IIA of the Act;

“treating practitioner” has the same meaning as in paragraph 16A (1) (a) of the Act.

11. (2) If a service described in an item in Group P10 or P11 is rendered by, or on behalf of, an approved pathology practitioner who is a recognised pathologist, the relevant one of those items does not apply to the service if:

(a) the service is rendered upon a request made in the course of an out-patient service at a recognised hospital; or

(b) the service is rendered upon a request made for a patient who is a private patient in a recognised hospital when the request is made; or

(d) a member of the staff of a recognised hospital, or a prescribed laboratory, participates in the service in the course of the member’s employment with the hospital or laboratory.

11. (3) An item in Group P10 or P11 does not apply to a pathology service to which subsection 16A (7) of the Act applies.

11. (4) An item in Group P10 or P11 does not apply to a pathology service unless at least one item in Groups P1 to P8 also applies to that service.

11. (5) Subject to subrule (7), if one item in Group P10 applies to a patient episode, no other item in that Group applies to that patient episode.

11. (6) An item in Group P11 applies only to the approved pathology practitioner or approved pathology authority to whom the specimen mentioned in the item was referred.

11. (7) If, in respect of the same patient episode:

(a) services referred to in 1 or more items in Group P5 and one or more of Groups P1, P2, P3, P4, P6, P7 and P8 are rendered by an approved pathology practitioner in the laboratory of another approved pathology authority; and

(b) services referred to in 1 or more items in Group P6 and one or more of Groups P1, P2, P3, P4, P5, P7 and P8 are rendered by another approved pathology practitioner in another approved pathology authority;

the fee specified in the applicable item in Group P10 is payable to both approved pathology practitioners.

11. (8) If more than one specimen is collected from a person on the same day for the provision of pathology services:

(a) in accordance with more than one request; and

(b) in or by a single approved pathology authority;

only a single amount specified in the applicable item in Group P10 is payable for the services.

11. (9) The amount specified in item 73921 is payable only once in respect of a single patient episode.

Application of an item in Group P11 (Specimen referred) to a service excludes certain other items

12. If item 73921 applies to a patient episode, none of the items in Group P10 applies to any pathology service rendered by the approved pathology authority or approved pathology provider who claimed item 73921 in respect of that patient episode.

Circumstances in which an item in Group P11 (Specimen referred) does not apply

13. (1) An item in Group P11 does not apply to a referral if:

(a) a service in respect of the same patient episode has been carried out by the referring approved pathology authority; and

(b) the approved pathology authority to which the referral is made is related to the referring approved pathology authority.

13. (2) An approved pathology authority is related to another approved pathology authority for the purposes of subclause (1) if:

(a) both approved pathology authorities are employed (including employed under contract) by the same person, whether or not that person is also an approved pathology authority; or

(b) either of the approved pathology authorities is employed (including employed under contract) by the other; or

(c) if both of the approved pathology authorities are corporations—the approved pathology authorities are related corporations within the meaning of the Corporations Law; or

(d) the approved pathology authorities are partners (whether or not either or both of the approved pathology authorities are individuals and whether or not other persons are in partnership with either or both of the approved pathology authorities).

Abbreviations

14. (1) The abbreviations in Part 3 of this Table may be used to identify particular pathology services or groups of pathology services.

14. (2) The names of services not listed in Part 3 of this Table must be written in full.

____________

GROUP P1—HAEMATOLOGY

Item number	Pathology service	Fee $
65001	Erythrocyte count, C-reactive protein, erythrocyte sedimentation rate, blood viscosity, haematocrit, haemoglobin, platelet count, leucocyte count, or reticulocyte count—1 or 2 tests	5.65
65003	3 or more tests described in item 65001, and calculation or measurement of cell index or indices	7.75
65005	Examination of blood film, or 5 part differential cell count, or both 5 part differential cell count and examination of blood film, including (if performed): (a) a service described in item 65027; and (b) any of the following services: (i) examination of blood film by special stains to demonstrate Heinz bodies, parasites or iron; (ii) examination of a blood film with alpha-naphthyl acetate esterase, chloroacetate esterase, neutrophil alkaline phosphatase, nitroblue tetrazolium, periodic acid Schiff or Sudan Black stains; (iii) Kleihauer test for HbF on blood film	10.25
65007	Full blood examination (consisting of the services described in items 65003 and 65005)	17.20
65009	Haemolysis or metabolic enzymes—assessment by: (a) erythrocyte autohaemolysis test; (b) erythrocyte fragility test; (c) sugar water test; (d) erythrocyte metabolic enzyme test; (e) heat denaturation test; (f) isopropanol precipitation test; (g) acid haemolysis test; and (h) quantitation of muramidase in serum or urine; 1 or more tests	23.60
65011	Haemoglobinopathy, tests for the diagnosis of, consisting of haemoglobin electrophoresis and 2 of: (a) examination for HbH; or (b) quantitation of HbA2; or (c) quantitation of HbF; including a service described in item 65001, 65003, 65005 or 65007 (if performed)	36.75
65013	Bone marrow trephine biopsy—histopathological examination of sections of bone marrow, including (if performed): (a) examination of aspirated material; and (b) special stains or immunochemical techniques (if any); and (c) a service described in item 65001, 65003, 65005, 65007 or 65015	112.90
65015	Bone marrow—examination of aspirated material (including clot sections where necessary), including (if performed): (a) special stains or immunochemical techniques (if any); and (b) a service described in item 65001, 65003, 65005 or 65007	82.00
65017	Blood grouping (including back-grouping if performed)—ABO and Rh (D antigen)	9.90
65019	Blood grouping—Rh phenotypes, Kell system, Duffy system, M and N factors or any other blood group system—1 or more systems, including a service described in item 65017 (if performed)	19.75
65021	Blood grouping (including back-grouping if performed), and examination of serum for Rh and other blood group antibodies, including: (a) identification and quantitation of any antibodies detected; and (b) (if performed) a service described in item 65001, 65003, 65005 or 65007	36.75
65023	Compatibility tests—all tests performed on any 1 day, including: (a) all grouping checks of patient and donor; and (b) examination for antibodies, and, if necessary, quantitation of any antibodies detected; and (c) a service described in item 65001, 65003, 65005, 65007, 65017 or 65021 (if performed)	99.75
65025	Examination of serum for blood group antibodies (including identification and, if necessary, quantitation of any antibodies detected)	16.25
65027	1 or more of the following tests: (a) direct Coombs test; (b) qualitative or quantitative test for cold agglutinins or heterophile antibodies; (c) qualitative spectroscopic examination of blood for abnormal haemoglobins; (d) qualitative test for red cell porphyrins and detection of metalbumin (Schumm’s test)	8.95
65029	Skin bleeding time, coagulation time, prothrombin time, activated partial thromboplastin time, thrombin time (including test for presence of an inhibitor and serial tests for fibrinolysis), test for factor XIII deficiency, fibrinogen, or 1 of: fibrinogen degradation products, fibrin monomer or D-dimer—1 test	12.40
65031	2 tests described in item 65029	16.40
65033	3 tests described in item 65029	20.40
65035	4 or more tests described in item 65029	24.40
65037	Quantitation, by 1 or more techniques, of: plasminogen, antithrombin III, Protein C, Protein S, heparin cofactor II euglobulin clot lysis time and test for lupus anticoagulant—1 to 3 tests	24.35
65039	4 or more tests described in item 65037	77.35
65041	Platelet aggregation in response to ADP, collagen, 5HT, ristocetin or similar substance—1 or more tests	48.70
65043	Heparin quantitation when monitoring a patient on subcutaneous heparin or low molecular weight heparin—1 or more tests	32.50
65045	Quantitation of Von Willebrand’s factor antigen (factor VIII related antigen), Von Willebrand’s factor (ristocetin cofactor), factor II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, Fletcher factor, Fitzgerald factor, or Passovy factor—1 test	32.45
65047	2 tests described in item 65045	46.75
65049	3 or more tests described in item 65045	61.05

GROUP P2—CHEMICAL

66201	Quantitation in serum, plasma, urine or other body fluid, by any method except reagent strip (with or without reflectance meter or electrophoresis) of: alanine aminotransferase, albumin, alkaline phosphatase, amylase, aspartate aminotransferase, bicarbonate, bilirubin (total), bilirubin (any fractions), calcium (total, dialysed or ionised), chloride, creatine kinase, creatine kinase isoenzymes (if not performed as described in item 66249), creatinine, fructosamine, gamma glutamyl transpeptidase, globulin, glucose, lactate dehydrogenase, lipase, lithium, magnesium, phosphate, potassium, total protein, sodium, urate or urea—1 test	9.55
66203	2 tests described in item 66201	11.60
66205	3 tests described in item 66201	13.65
66207	4 tests described in item 66201	15.70
66209	5 tests described in item 66201	17.75
66211	6 or more tests described in item 66201	19.80
66213	Test by any method (except reagent strip or dip-stick): (a) for the presence of: (i) the following urine constituents—bilirubin, cystine (cysteine), haemoglobin, melanin (melanogen), myoglobin, porphobilinogen, porphyrins, urobilinogen; or (ii) cryoglobulins or cryofibrinogen in plasma; or (b) of pH of body fluids other than urine (not including urine acidification test); 1 or more tests	9.70
66215	Quantitation of cryoglobulins or cryofibrinogen following their detection in a test described in item 66213, including that service—1 or more tests	14.70
66221	Test for faecal occult blood (including tests for haemoglobin and its derivatives in the faeces) by: (a) an immunological method; and (b) a chemical method (except reagent strip or dip-stick); each test, to a maximum of 3 tests taken on separate days in a 28 day period	8.80.
66223	Osmolality, estimation by osmometer, in serum or in urine—1 or more tests	24.35
66225	Quantitation of: (a) blood gases (including pO2, oxygen saturation and pCO2); and (b) bicarbonate and pH; including any other measurement (e.g., haemoglobin or potassium) or calculation performed on the same specimen—1 or more tests on 1 specimen	33.25
66227	Quantitation of blood gases, bicarbonate and pH as described in item 66225 on each specimen in excess of 1 to a maximum of 6 specimens within any 1 day	8.80
66229	Calculus, analysis of 1 or more	30.20
66231	All qualitative and quantitative tests on blood, urine or other body fluid for: (a) a drug or drugs of abuse (including illegal drugs and legally available drugs taken other than in appropriate dosage); or (b) ingested or absorbed toxic chemicals; including a service described in item 66235, 66237 or 66239 (if performed), but excluding: (c) the surveillance of sports people and athletes for performance improving substances; and (d) the monitoring of patients participating in a drug abuse treatment program	41.00
66235	Quantitation, not elsewhere described in this Table by any method or methods, in blood or other body fluid, of a drug being used therapeutically by the patient from whom the specimen was taken—1 test	20.45
	(Item is subject to rule 6)
66237	2 tests described in item 66235	28.65
	(Item is subject to rule 6)
66239	3 or more tests described in item 66235	36.85
66241	Tests described in item 66235, if rendered under a request referred to in subparagraph (2) (a) (iii) of rule 6 (Item is subject to rule 6)	8.20.
66243	Amniotic fluid, spectrophotometric examination of, and quantitation of: (a) lecithin/sphingomyelin ratio; or (b) palmitic acid, phosphatidylglycerol or lamellar body phospholipid; 1 or more tests	32.50
66247	Electrophoresis (including quantitation), of serum and either or both urine or other body fluid all collected within a 28 day period, to demonstrate protein classes or presence of paraprotein, including the preliminary quantitation of: (a) total protein, albumin and globulin; or (b) total relevant enzyme activity; 2 or more tests	49.85
66249	Electrophoresis, quantitative or qualitative, of serum, urine or other body fluid to demonstrate: (a) protein classes; or (b) presence and amount of paraprotein; or (c) the isoenzymes of lactate dehydrogenase, alkaline phosphatase and creatine kinase; including the preliminary quantitation of total protein, albumin and globulin or of total relevant enzyme activity	35.20
66250	Electrophoresis, quantitation or qualitative, of serum, for demonstration of lipoprotein subclasses, if the cholesterol is >6.5 mmol/l and triglyceride >3.0 mmol/l or in the diagnosis of types III and IV hyperlipidaemia—each episode to a maximum of 2 episodes in a 12 month period	30.20
66255	Alpha-1-acid glycoprotein, alpha-1-antitrypsin, or alpha-2-macroglobulin—quantitation in serum, urine or other body fluid—1 or more tests	19.90
66257	C-1 esterase inhibitor—quantitation	19.90
66258	C-1 esterase inhibitor—functional assay	44.50
66261	CA-125 antigen, CA-15.3 antigen, CA-19.9 antigen, carcinoembryonic antigen (CEA), mammary serum antigen, mucin-like carcinoma-associated antigen (1 or more fractions), neuron-specific enolase, or thyroglobulin in serum or other body fluid, in the monitoring or confirmation of malignancy—quantitation—1 test	19.90
66262	2 or more tests described in item 66261	36.65
66263	Iron studies, consisting of quantitation of: (a) serum iron; (b) transferrin or iron binding capacity; and (c) ferritin	36.70
66265	Serum B12 or serum folate—1 or more tests within a 28-day period	24.35
66267	Red cell folate and serum B12, and, if required, serum folate, to a maximum of 3 episodes in a 12-month period	44.45
66269	Vitamins—quantitation of vitamins A, B1, B2, B3, B6, C, and E in blood, urine or other body fluid—1 or more tests within a 6-month period	30.20
66271	Vitamin D or D fractions—1 or more tests	30.20
66277	Quantitation of aluminium (except if item 66325 applies), arsenic, beryllium, cadmium, copper, chromium, gold, manganese, mercury, nickel, selenium, or strontium, in blood, urine or other body fluid or tissue—1 or more tests in a 6-month period	35.35
66279	Blood lead quantitation (other than for occupational health screening purposes) to a maximum of 3 tests in a 6–month period—each test	30.20
66281	Porphyrins (1 or more fractions), catecholamines (1 or more fractions), hydroxymethoxymandelic acid (HMMA), homovanillic acid (HVA), metanephrines, methoxyhydroxyphenylethylene glycol (MHPG), or phenylacetic acid (PAA)—quantitation—1 or more tests	39.45
66283	Quantitation of: (a) faecal fat; or (b) breath hydrogen in response to loading with disaccharides; 1 or more tests within a 28-day period	39.45
66285	Enzymes—quantitation of 1 or 2 in solid tissue or tissues other than blood elements	39.45
66287	Quantitation of 3 to 5 enzymes as described in item 66285	73.45
66289	Quantitation of 6 or more enzymes as described in item 66285	97.45
66293	Thyrotrophin releasing hormone (TRH) test, including provision and administration of TRH and quantitation of hormones	48.70
66295	Personal performance by a recognised pathologist of 1 or more of the following: (a) growth hormone suppression by glucose loading; (b) growth hormone stimulation by exercise; (c) dexamethasone suppression test; (d) L-dopa stimulation of growth hormone	11.60
66297	Personal performance by a recognised pathologist of 1 of the following: (a) gonadotrophin releasing hormone stimulation test; (b) synacthen stimulation test; (c) glucagon stimulation test with C-peptide measurement; (d) pentagastrin stimulation of thyrocalcitonin release; (e) secretin stimulation of gastrin release; (f) insulin hypoglycaemia; (g) arginine infusion	38.70
66299	Personal performance by a recognised pathologist of 2 or more tests described in item 66297	61.90
66315	Quantitation of hormone receptors on proven primary breast or ovarian carcinoma or a metastasis from a breast or ovarian carcinoma or a subsequent lesion in the breast—1 or more tests	78.90
66317	Quantitation of HDL cholesterol or apolipoprotein B/A1 ratio in a patient who: (a) has a serum cholesterol level >5.5 mmol/1; or (b) has a fasting serum triglyceride level >2.0 mmol/1; or (c) is on a lipid lowering drug prescribed by a medical practitioner; each episode to a maximum of 4 episodes in a 12 month period (Item is subject to rule 7A)	12.35
66319	Quantitation of glycosylated haemoglobin performed in the management of established diabetes—each test to a maximum of 4 tests in a 12-month period	16.60
66321	Quantitation, in the 2nd trimester of pregnancy, of alpha fetoprotein, human chorionic gonadotrophin, oestriol and any other substance to detect foetal abnormality, including a service described in 1 or more of items 66353, 66373, 73527 and 73529 (if performed)—1 patient episode in a pregnancy	54.50
66323	Test for tryptic activity in faeces in the investigation of diarrhoea of longer than 4 weeks duration in children under 6 years old	11.00
66325	Quantitation of serum aluminium in a patient in a renal dialysis program—each test	35.35
66327	TSH—quantitation, requested as a preliminary test to thyroid function testing	31.55
66329	Thyroid function tests (comprising the service described in item 66327 and 1 or more of the following tests—estimation of free thyroxine index, free thyroxine, free T3, total T3, thyroxine binding globulin) in respect of a patient, if at least one of the following conditions is satisfied: (a) the patient has an abnormal level of TSH;	41.00
	(b) the tests are performed for the purpose of: (i) monitoring thyroid disease in the patient; or (ii) if the patient is in a hospital—investigating thyroid function in the patient; or
	(iii) investigating dementia or psychiatric illness of the patient; or (iv) investigating amenorrhoea or infertility of the patient; (c) the medical practitioner who requested the tests suspects the patient has pituitary dysfunction; (d) the patient is on drugs that interfere with thyroid hormone metabolism or function (Item is subject to rule 7B)
66331	Quantitation (except by reagent strip with or without reflectance meter or electrophoresis) of cholesterol or triglycerides or both in serum, plasma, urine or other body fluid	11.40
66335	A service described in item 66331 and 1 test described in item 66201	13.65
66337	A service described in item 66331 and 2 tests described in item 66201	15.70
66339	A service described in item 66331 and 3 tests described in item 66201	17.75
66341	A service described in item 66331 and 4 or more tests described in item 66201	19.80
66343	Detection or quantitation or both (not including the detection of nicotine and metabolites in smoking withdrawal programs) of a drug, or drugs, of abuse or a therapeutic drug, on a sample collected from a patient: (a) participating in a drug abuse treatment program; or (b) being treated for drug effects; including all tests on blood, urine or other body fluid—each episode, to a maximum of 21 episodes in a 12-month period	20.50
66353	Quantitation in serum or other body fluids of alpha fetoprotein, except if requested as part of item 66321	19.90
66355	Ferritin—quantitation, except if requested as part of iron studies	19.90
66357	Prostate specific antigen or prostatic acid phosphatase—quantitation in the confirmation or monitoring of malignancy—1 test	19.90
66359	2 tests described in item 66357	36.65
66361	Beta-2-microglobulin, caeruloplasmin, haptoglobins, microalbumin in proven diabetes mellitus, or prealbumin—quantitation in serum, urine or other body fluids—1 test	19.90
66363	2 or more tests described in item 66361	36.65
66367	Quantitation of acetoacetate, alcohol, amino acids, ammonia, angiotensin converting enzyme, beta-hydroxybutyrate, cholinesterase, cysteine, total free fatty acids, histamine, hydroxyindoleacetic acid, hydroxyproline, lactate, oxalate, pyruvate, serotonin, xylose, or zinc—1 test	24.35
66369	2 or more tests described in item 66367	38.30
66373	Human placental lactogen or oestriol—quantitation, except if requested as part of item 66321—1 test	31.55
66375	2 tests described in item 66373	42.60
66405	Quantitation of hormones and hormone binding proteins—ACTH, aldosterone, androstenedione, C-peptide, calcitonin, cortisol, cyclic AMP, DHEAS, 11-deoxycortisol, dihydrotestosterone, FSH, gastrin, glucagon, growth hormone, hydroxyprogesterone, insulin, LH, oestradiol, oestrone, progesterone, prolactin, PTH, renin, sex hormone binding globulin, somatomedin C(lgF1), free or total testosterone, TSH (where not requested on its own or as part of a thyroid function test), urine steroid fraction or fractions, vasoactive intestinal peptide, vasopressin (antidiuretic hormone)—1 test	31.55
	(Item is subject to rule 6)
66407	2 tests described in item 66405	42.55
	(Item is subject to rule 6)
66409	3 tests described in item 66405	53.55
	(Item is subject to rule 6)
66411	4 tests described in item 66405	64.55
	(Item is subject to rule 6)
66413	5 tests described in item 66405	75.55
	(Item is subject to rule 6)
66415	6 or more tests described in item 66405	86.55
66417	Tests described in item 66405, if rendered under a request referred to in subparagraph (2) (a) (iii) of rule 6 (Item is subject to rule 6)	11.05
66419	Oral glucose tolerance test for the diagnosis of diabetes mellitus that includes the following: (a) administration of glucose; (b) at least 3 estimations of blood glucose; (c) if performed, any test described in item 66405	17.70

GROUP P3—MICROBIOLOGY

69201	Microscopy of wet film material other than blood, from 1 or more sites, obtained directly from a patient (not cultures) including: (a) differential cell count (if performed); or (b) examination for dermatophytes; or (c) dark ground illumination; or (d) stained preparation or preparations, using any relevant stain or stains; 1 or more tests	7.35
69203	Microscopy of faeces for parasites using concentration techniques (including the use of appropriate stains) to a maximum of 3 tests taken on separate days, including a service (if performed) described in item 69201—each test	12.35
69205	Culture and (if performed) microscopy to detect pathogenic micro-organisms (including fungi but excluding viruses), from nasal swabs, throat swabs, eye swabs and ear swabs, including (if performed): (a) pathogen identification and antibiotic susceptibility testing; or (b) the detection of antigens not elsewhere described in this Table; or (c) a service described in item 69201; specimens from 1 or more sites	19.35
69207	Microscopy and culture to detect pathogenic micro-organisms, including fungi but excluding viruses, from: (a) skin or other superficial sites, urethra, vagina, cervix or rectum (except for faecal pathogens); or (b) specimens of sputum (except when part of item 69213); including (if performed): (c) the detection of antigens not elsewhere specified in this Table; or (d) pathogenic identification and antibiotic susceptibility testing; or (e) a service described in items 69201, 69205 and 73810; 1 or more tests on 1 or more specimens	28.25
69209	Microscopy and culture of postoperative wounds, aspirates of body cavities, synovial fluid, CSF or operative or biopsy specimens, for the presence of pathogenic micro-organisms (including fungi but excluding viruses) involving aerobic and anaerobic culture and the use of different culture media, and including (if performed): (a) pathogen identification and antibiotic susceptibility testing; (b) the detection of antigens not elsewhere specified in this Table; or (c) a service described in item 69201, 69205 or 69207; specimens from 1 or more sites	38.30
69211	Culture of faeces for faecal pathogens, involving the use of at least 2 selective or enrichment media and culture in at least 2 different atmospheres and including (if performed): (a) pathogen identification and antibiotic susceptibility testing; (b) the detection of clostridial toxins or antigens not elsewhere specified in this Table; or (c) a service described in item 69201; to a maximum of 3 specimens in any 7-day period—each test	46.45
69213	Microscopy with appropriate stains and culture of 3 specimens of sputum, urine or other body fluids for mycobacteria including (if performed): (a) microscopy and culture of other bacterial pathogens; or (b) pathogen identification and antibiotic susceptibility testing; and (c) a service described in item 69201	64.95
69215	Blood culture for pathogenic micro-organisms (other than viruses), including sub-cultures and (if performed): (a) identification of any cultured pathogen; and (b) necessary antibiotic susceptibility testing; each set of cultures to a maximum of 3 sets	17.00
69217	Urine examination (including serial examination) by any means other than simple culture by dip slide, including: (a) cell count; and (b) culture; and (c) colony count (if performed); and (d) stained preparations; and (e) identification of cultured pathogens; and (f) antibiotic susceptibility testing; and (g) any examination for pH, specific gravity, blood, albumin, urobilinogen, sugar, acetone or bile salts	20.55
69219	Detection of: (a) the antigens of Haemophilus influenzae, Streptococcus pneumoniae, Neisseria, meningitidis, Group B streptococcus respiratory syncytial virus, cryptococcal antigens or Varicella zoster; or (b) Clostridium difficile toxin (except if the service described in item 69211 has been performed); 1 or more tests	16.25
69221	Detection of Chlamydia from material obtained directly from a patient (not cultures)—1 or more tests	9.70
69223	Detection of herpes simplex virus from material obtained directly from a patient (not cultures)—1 or more tests	9.70
69229	Quantitation of 1 antibody to microbial or exogenous antigens not elsewhere described in the Schedule—1 test	13.90
	(Item is subject to rule 6)

69231	2 tests described in item 69229	21.30
	(Item is subject to rule 6)
69233	3 tests described in item 69229	28.70
	(Item is subject to rule 6)
69235	4 tests described in item 69229	36.10
	(Item is subject to rule 6)
69237	5 tests described in item 69229	43.50
	(Item is subject to rule 6)
69239	6 or more tests described in item 69229	50.90
69241	Tests described in item 69229, if rendered under a request referred to in subparagraph (2) (a) (iii) of rule 6 (Item is subject to rule 6)	7.40
69243	Hepatitis B surface antigen test	13.75
69245	Hepatitis B serology to define the immune status of an individual, including at least hepatitis B surface antibody or hepatitis B core antibody test, and including a service described in item 69243, 69247 or 69249 (if performed)	18.60
69247	Serological tests to identify the agent causing acute hepatitis (must include hepatitis B surface antigen, hepatitis B core antibody and hepatitis A IgM antibody test and the services described in items 69243, 69245 and 69249)	36.75
69249	Tests performed in the follow-up of a patient with proven hepatitis B, including: (a) hepatitis B surface antigen test; and (b) either: (i) hepatitis Be antigen test; or (ii) hepatitis B surface antibody test, and (c) (if performed) services described in items 69243 and 69245	26.70
69251	Antibiotics or antimicrobial chemotherapeutic agents in serum, urine or other body fluid—quantitation—1 or more tests	24.35
69253	Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness during that pregnancy) including: (a) the determination of 1 of the following: rubella immune status, specific syphilis serology, hepatitis B surface antigen; and (b) a service described in 1 or more of items 69229, 69243 and 69245 (if performed)	13.90
69255	Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness during that pregnancy) including: (a) the determination of 2 of the following: rubella immune status, specific syphilis serology or hepatitis B surface antigen; (b) a service described in 1 or more of items 69229, 69243 and 69245 (if performed)	21.25
69257	Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness during that pregnancy) including: (a) the determination of all 3 of the following: rubella immune status, specific syphilis serology and hepatitis B surface antigen); and (b) a service described in 1 or more of items 69229, 69243 and 69245 (if performed)	28.25
69261	Examination for chlamydia (by culture or by the demonstration of chlamydial nucleic acid using a DNA probe) in material obtained directly from a patient, including a service described in item 69221, 69223 or 69263 (if performed)	18.05
69263	Examination for herpes simplex virus of one or more types by culture in material obtained directly from a patient, including a service described in item 69221, 69223 or 69261 (if performed)	28.15
69265	Hepatitis C antibody test	13.90

GROUP P4—IMMUNOLOGY

71061	Immunoelectrophoresis or immunofixation, of serum, urine or other body fluid, and characterisation of, a paraprotein or cryoglobulin not previously characterised, including a service described in 1 or both of items 66213 and 66215 (if performed)—1 or more tests	28.80
71063	Immunoelectrophoresis or immunofixation of serum and urine concurrently collected, and characterisation of, a paraprotein not previously characterised—2 or more tests	43.45
71065	Examination of CSF and serum concurrently collected for the presence of oligoclonal proteins—2 or more tests	43.45
71067	Quantitation of total immunoglobulins A, G, M or D by any method in serum, urine or other body fluid—1 test	14.85
71069	2 tests described in item 71067	23.45
71071	3 or more tests described in item 71067	32.05
71073	Quantitation of all 4 immunoglobulin G subclasses, with a maximum of 2 patient episodes in a 12-month period—each patient episode	104.75
71075	Quantitation of immunoglobulin E (total), with a maximum of 2 patient episodes in a 12-month period—each patient episode	26.70
71077	Quantitation of immunoglobulin E (total) in the follow-up of a patient with proven immunoglobulin-E-secreting myeloma, proven congenital immunodeficiency or proven allergic bronchopulmonary aspergillosis, with a maximum of 6 patient episodes in a 12-month period—each patient episode	26.70
71079	Detection of specific immunoglobulin G or E antibodies to single or multiple potential allergens, with a maximum of 4 patient episodes in a 12 month period—each patient episode	24.10
71081	Quantitation of total haemolytic complement	19.90
71083	Quantitation of complement components C3 and C4 or properdin factor B—1 test	19.90
71085	2 tests described in item 71083	28.55
71087	3 or more tests described in item 71083	37.20
71089	Quantitation of complement components or breakdown products of complement proteins not elsewhere described in an item in this Schedule—1 test	28.75
71091	2 tests described in item 71089	52.10
71093	3 or more tests described in item 71089	75.45
71097	Antinuclear antibodies—detection in serum or other body fluids, including quantitation if required	25.10
71099	Double-stranded DNA antibodies—quantitation by 1 or more methods other than the Crithidia method	26.20
71101	Antibodies to 1 or more extractable nuclear antigens—detection in serum or other body fluids	17.15
71103	Characterisation of an antibody detected in a service described in item 71101 (including that service)	51.35
71106	Rheumatoid factor—detection by any technique in serum or other body fluids, including quantitation if required	11.15
71109	Antibodies to tissue antigens (acetylcholine receptor, adrenal cortex, cardiolipin, glomerular basement membrane, heart, histone, insulin, insulin receptor, intrinsic factor, islet cell, lymphocyte, neuron, neutrophil cytoplasm, ovary, parathyroid, platelet, salivary gland, skeletal muscle, skin basement membrane and intercellular substance, thyroglobulin, thyroid microsome or thyroid stimulating hormone receptor)—detection, including quantitation if required, of 1 antibody	34.10
71113	Detection of 2 antibodies described in item 71109	46.80
71115	Detection of 3 antibodies described in item 71109	59.50
71117	Detection of 4 antibodies described in item 71109	72.20
71119	Antibodies to tissue antigens not elsewhere specified in this Table—detection, including quantitation if required, of 1 antibody	17.10
71121	Detection of 2 antibodies specified in item 71119	20.50
71123	Detection of 3 antibodies specified in item 71119	23.90
71125	Detection of 4 or more antibodies specified in item 71119	27.30
71127	Functional tests for lymphocytes—quantitation other than by microscopy of: (a) proliferation induced by 1 or more mitogens; or (b) proliferation induced by 1 or more antigens; or (c) estimation of 1 or more mixed lymphocyte reactions; including a test described in item 65005 (if performed), with a maximum of 2 patient episodes in a 12-month period—each patient episode	174.05
71129	2 tests described in item 71127	215.00
71131	3 or more tests described in item 71127	255.95
71135	Quantitation of neutrophil function, comprising at least 2 of the following: (a) chemotaxis; (b) phagocytosis; (c) oxidative metabolism; (d) bactericidal activity; including any test described in item 65005 (other than nitroblue tetrazolium reduction slide test), with a maximum of 2 patient episodes in a 12-month period—each patient episode	205.25
71137	Quantitation of cell-mediated immunity by multiple antigen delayed type hypersensitivity intradermal skin testing using a minimum of 7 antigens, with a maximum of 2 patient episodes in a 12-month period—each patient episode	29.85
71139	Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations, including a total lymphocyte count by any method, on 1 or more specimens of blood, CSF or serous fluid	102.65
71141	Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations on 1 or more disaggregated tissue specimens	194.80
71143	Characterisation (but not monitoring) of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations in an immunological or haematological malignancy, including a service described in 1 or both of items 71139 and 71141 (if performed) , on a specimen of blood, CSF, serous fluid or disaggregated tissue	256.60
71145	Characterisation (but not monitoring) of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations in an immunological or haematological malignancy, including a service described in 1 or more of items 71139, 71141 and 71143 (if performed), on 2 or more specimens of disaggregated tissues or 1 specimen of disaggregated tissue and 1 or more specimens of blood, CSF or serous fluid	418.95
71147	HLA-B27 typing	32.00
71149	Complete tissue typing for 4 HLA-A and HLA-B Class I antigens (including any separation of leucocytes), including a service described in item 71147 (if performed)	106.85
71151	Tissue typing for HLA-DR, HLA-DP and HLA-DQ Class II antigens (including any separation of leucocytes)—phenotyping or genotyping of 2 or more antigens	117.30

GROUP P5—TISSUE PATHOLOGY

72801	Examination of biopsy material (gross and microscopic) including all tissue processing, staining, and except as provided for in 72805 and 72807—all professional opinions	79.05
72803	Intraoperative frozen section diagnosis of biopsy material, including any other tissue pathology service in Group P5	148.80
72805	Immunohistochemical staining of biopsy material by 1 or more labelled antibody techniques (including immunofluorescence and immunoperoxidase) and including any other tissue pathology service in Group P5	107.45
72807	Electron microscopy of biopsy material including any other tissue pathology service in Group P5	153.65

GROUP P6—CYTOLOGY

73043		Cytology (including serial examinations) of nipple discharge or smears from skin, lip, mouth, nose or anus for detection of precancerous or cancerous changes—1 or more tests		15.00
73045	Cytology (including serial examinations) for malignancy (other than an examination mentioned in item 73053); and including any Group P5 service, if performed on: (a) specimens resulting from washings or brushings from sites not specified in item 73043; or (b) a single specimen of sputum or urine; or (c) 1 or more specimens of other body fluids; 1 or more tests		29.35
73047		Cytology of a series of 3 sputum or urine specimens for malignant cells		61.10
73049		Cytology material obtained directly from a patient by fine needle aspiration of solid tissue or tissues		51.75
73051		Cytology material obtained directly from a patient by fine needle aspiration of solid tissue or tissues if: (a) the aspiration is performed by a recognised pathologist; or (b) a recognised pathologist attends the aspiration and performs cytological examination during the attendance		88.85
73053		Cytology of smears from cervix: (a) for detection of precancerous or cancerous changes in women with no symptoms, signs or recent history suggestive of cervical neoplasia; or (b) due to an unsatisfactory smear taken in the circumstances defined in para (a) above ; each examination		13.80
73055		Cytology not associated with item 73053, of smears from cervix in association with: (a) the management of previously detected abnormalities including precancerous or cancerous conditions; or (b) the investigation of women with symptoms, signs or recent history suggestive of cervical neoplasia; each test		13.80
73057		Cytology of smears from vagina, not associated with item 73053 or 73055 nor to monitor hormone replacement therapy—each test		13.80

GROUP P7—CYTOGENETICS

73287	Chromosome studies including preparation, count, karyotyping and identification by banding techniques or fragile X-site determination of one or more of any tissue or fluid except blood—1 or more tests	327.60
73289	Chromosome studies including preparation, count, karyotyping and identification by banding techniques or fragile X-site determination of blood—1 or more tests	296.85

GROUP P8—INFERTILITY AND PREGNANCY TESTS

73521	Semen examination for presence of spermatozoa, or examination of cervical mucus for spermatozoa (Huhner’s test)	6.80
73523	Semen examination (other than post-vasectomy semen examination), including: (a) measurement of volume, sperm count, and motility; and (b) examination of stained preparations; and (c) morphology; and (if performed) (d) differential count and 1 or more chemical tests; with a maximum of 4 episodes in a 12-month period—each episode	28.25
73525	Sperm antibodies—sperm-penetrating ability—1 or more tests	18.20
73527	Chorionic gonadotrophin (beta-HCG)— detection in serum or urine by 1 or more methods, including serial dilution if performed, for diagnosis of pregnancy—1 or more tests	9.90
73529	Chorionic gonadotrophin (beta-HCG)—quantitation in serum by 1 or more methods for diagnosis of hydatidiform mole, HCG-secreting neoplasm, or threatened abortion, or follow-up of abortion or diagnosis of ectopic pregnancy, including any services performed in 73527—1 test	28.25

GROUP P9—SIMPLE BASIC PATHOLOGY TESTS

73801	Semen examination for presence of spermatozoa	6.50
73802	Leucocyte count, erythrocyte sedimentation rate, examination of blood film (including differential leucocyte count), haemoglobin, haematocrit or erythrocyte count—1 test	4.30
73803	2 tests described in item 73802	6.00
73804	3 or more tests described in item 73802	7.70
73805	Microscopy of urine whether stained or not, or catalase test	4.30
73806	Pregnancy test by 1 or more immunochemical methods	9.90
73807	Microscopy for wet film other than urine, including any relevant stain	6.50
73808	Microscopy of Gram-stained film, including (if performed) a service described in item 73805 or 73807	8.15
73809	Chemical tests for occult blood in faeces by reagent stick, strip, tablet or similar method	2.20
73810	Microscopy for fungi in skin, hair or nails—1 or more sites	6.50
73811	Mantoux test	10.60

GROUP P10—PATIENT EPISODE INITIATION

73901	Initiation of a patient episode that consists only of a service described in item 73053, 73055 or 73057 from a person who is not in a recognised hospital or a prescribed laboratory	7.85
73903	Initiation of a patient episode that consists only of a service described in item 72801 from a person who is an in-patient of a hospital other than a recognised hospital	14.15
73905	Initiation of a patient episode that consists only of a service described in item 72801 from a person who is not an in-patient of a private hospital and not a patient of a recognised hospital	7.85
73907	Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905 or in Group P9) if the specimen is collected in a licensed collection centre	16.25
73909	Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905 or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person who is an in-patient of a hospital other than a recognised hospital	16.25
73911	Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905 or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person in the place where the person was residing or in a nursing home or institution	10.00
73913	Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905 or 73907 or items in Group P9) if the specimen is collected from the person by the person	10.00
73915	Initiation of a patient episode by collection of a specimen for a service (other than a service described in items 73901, 73903 or 73905 or items in Group P9) if the specimen is collected by or on behalf of the treating practitioner	10.00

GROUP P11—SPECIMEN REFERRED

73921

Receipt of specimen by an approved pathology practitioner of an approved pathology authority from another approved pathology practitioner of a different approved pathology authority or another pathology authority

10.00”.

(Item is subject to subrule 11 (9))

Amniotic fluid examination AFE 66243

Amylase AMS 66201

Amylobarb AMYL 66235

Androstenedione ANDR 66405

Angiotensin converting enzyme ACE 66367

Antibiotic and antimicrobial chemotherapeutic agents—quantitationQAA 69251

Antibodies to extractable nuclear antigens—detectionENA 71101

Antibodies to extractable nuclear antigens—characterisation of antibodies if positive ENAENAP 71103

Antibodies to nuclear antigens—detection ANA 71097

Antibodies to nuclear antigens—quantitation and measurement of DNA binding if positive ANA ANAP 71099

Antibodies to tissue antigens—acetylcholine receptorARA 71109

Antibodies to tissue antigens—adrenal cortex ADR 71109

Antibodies to tissue antigens—cardiolipin ACL 71109

Antibodies to tissue antigens—centromere ACA 71119

Antibodies to tissue antigens—gastric parietal cellPCA 71119

Antibodies to tissue antigens—gliadin IgA GLIA 71119

Antibodies to tissue antigens—glomerular basement membrane GBA 71109

Antibodies to tissue antigens—heart AHE 71109

Antibodies to tissue antigens—histone AHI 71109

Antibodies to tissue antigens—insulin receptor antibodies INSA 71109

Antibodies to tissue antigens—intercellular cement substance of skinICCS 71109

Antibodies to tissue antigens—intrinsic factor AIF 71109

Antibodies to tissue antigens—islet cell AIC 71109

Antibodies to tissue antigens—Jo‑1 JO1 71119

Antibodies to tissue antigens—keratin KERA 71119

Antibodies to tissue antigens—liver/kidney microsomes LKA 71119

Antibodies to tissue antigens—lymphocyte ALY 71109

Antibodies to tissue antigens—mitochondria MA 71119

Antibodies to tissue antigens—neuron ANE 71109

Antibodies to tissue antigens—neutrophil cytoplasmANCA 71109

Antibodies to tissue antigens—ovary AOV 71109

Antibodies to tissue antigens—parathyroid PTHA 71109

Antibodies to tissue antigens—platelet APA 71109

Antibodies to tissue antigens—PM‑Sc1 PM1 71119

Antibodies to tissue antigens—reticulin RCA 71119

Antibodies to tissue antigens—salivary gland ASG 71109

Antibodies to tissue antigens—Scl‑70 SCL 71119

Antibodies to tissue antigens—skeletal muscle SLA 71109

Antibodies to tissue antigens—skin basement membrane SKA 71109

Antibodies to tissue antigens—smooth muscle SMA 71119

Antibodies to tissue antigens—thyroglobulin ATG 71109

Antibodies to tissue antigens—thyroid icrosome TMA 71109

Antibodies to tissue antigens—TSH receptor antibody test TSHA 71109

Antibody testing, microbial (see Microbial)

Antigen testing, microbial (see Microbial)

Antithrombin III ATH 65037

Anus—cytology on specimens from SMCY 73043

Apolipoprotein B/A1 ratio APO 66317

Arginine infusion ARIN 66297

Arsenic AS 66277

Aspartate aminotransferase AST 66201

Aspergillus—microbial antibody testing ASP 69229

Avian precipitins (bird fancier’s disease)—microbial antibody testing APP 69229

B12 vitamin RCF 66267

Barbiturate BARB 66235

Beryllium BE 66277

Beta‑hydroxybutyrate BHYB 66367

Beta‑2‑microglobulin BMIC 66361

Bicarbonate HCO3 66201

Bilirubin (all fractions) BILI 66201

Bilirubin (all fractions)—in urine UBIL 66213

Bilirubin (all fractions)—neonatal BILN 66365

Bird fancier’s disease (see avian precipitins)

Blastomyces—microbial antibody testing BLM 69229

Bleeding time BT 65029

Blood—compatibility testing XMAT 65023

Blood—culture BC 69215

Blood—faecal occult FOB 66221

Blood—film BF 65005

Blood—full examination FBE 65001

Blood—gases GAS 66225

Blood—group and blood group antibodies BGAB 65021

Blood—group antibodies BGA 65025

Blood—group systems BGS 65019

Blood—grouping‑ABO and RH (D antigen)BG 65017

Blood—viscosity VISC 65001

Body cavities, aspirations of—microscopy and culture of material from MCS3 69209

Body fluids—cytology BFCY 73045

Bone marrow examination—aspirate BMEA 65015

Bone marrow examination—trephine BMET 65013

Bordetella pertussis—microbial antibody testing BOR 69229

Borrelia burgdorferi—microbial antibody testing BOB 69229

Breath hydrogen test BHT 66283

Bromide BRMD 66235

Brucella—microbial antibody testing BRU 69229

C‑l esterase inhibitor—quantitation CEIQ 66257

C‑l esterase inhibitor—functional CEIF 66258

C‑Peptide CPEP 66405

C‑reactive protein CRP 65001

CA‑15.3 antigen CA15 66261

CA‑l9.9 antigen CA19 66261

CA‑125 antigen C125 66261

Cadmium CD 66277

Caeruloplasmin CPLS 66361

Calcitonin CALT 66405

Calcium (total, dialysed or ionized) CA 66201

Calculus analysis CALC 66229

Campylobacter jejuni—microbial antibody testingCAM 69229

Candida—microbial antibody testing CAN 69229

Carbamazepine (Tegretol) CARB 66235

Carboxyhaemoglobin COHB 65027

Carcinoembryonic antigen CEA 66261

Cardiac enzymes (see group tests in Division A)

Cardiolipin—tissue antigens—antibodies ACL 71109

Catecholamines CAT 66281

Cell mediated immunity—delayed type—hypersensitivity test CMI 71137

Centromere—tissue antigens—antibodies ACA 71119

Cervix—cytology—routine CCR 73053

Cervix—cytology—abnormalities CCRA 73055

Cervix—microscopy and culture of material fromMCS2 69207

Characterisation of antibodies if positive ENA ENAP 71103

Chemicals, toxic (ingested or absorbed)—assaysDRGO 66231

Chlamydia—direct detection from clinical materialCHLY 69221

Chlamydia—investigation by cultural methods CHLC 69261

Chlamydia—investigation by DNA probe CHLP 69261

Chlamydia—microbial antibody testing CHL 69229

Chlamydia—microbial antigen testing CHLY 69221

Chloral hydrate CHHY 66235

Chlorazepate CHZP 66235

Chloride CL 66201

Chloroquine CLOQ 66235

Chlorpromazine CHLO 66235

Cholesterol CHOL 66331

Cholesterol—HDL HDLC 66317

Cholinesterase CHSE 66367

Chorionic gonadotrophin—for pregnancy diagnosisHCG 73527

Chorionic gonadotrophin—for diagnosis of specified conditionsHCGD 73529

Chorionic gonadotrophin—for Down's syndrome and neural tube defect testing NTDD 66321

Chromium CR 66277

Chromosome identification and banding 73287-89

Chromosome identification studies—blood CSB 73289

Chromosome identification studies—other than bloodCS 73287

Cimetidine CMTD 66235

Clobazam CLOB 66235

Clomipramine CLOM 66235

Clonazepam (Rivotril) CLON 66235

Clostridium difficile—microbial antigen testing CLDT 69219

Coagulation—factors (see individual factors)

Coagulation—studies (see group tests in Division A)

Coagulation—time CT 65029

Coccidioides—microbial antibody testing CCC 69229

Cold agglutinins CAG 65005,

65027

Collection of specimen(s) for cytological examination 73051

Compatibility testing XMAT 65023

Complement, total haemolytic COM 71081

Complement, total haemolytic—components C3 C3 71083

Complement, total haemolytic—components C4 C4 71083

Complement, total haemolytic—properdin factor BPFB 71083

Complement, total haemolytic—other componentsCOMP 71089

Copper CU 66277

Cortisol CORT 66405

Coxsackie B1‑6—microbial antibody testingCOX 69229

Creatine kinase CK 66201

Creatine kinase—isoenzymes CKI 66201

Creatine kinase—isoenzymes (electrophoresis) CKIE 66249

Creatinine C 66201

Cryofibrinogen—qualitative CFID 66213

Cryofibrinogen—quantitative CFIE 66215

Cryoglobulins—qualitative CGLD 66213

Cryoglobulins—quantitative CGLE 66215

Cryoglobulins—investigation by immunoelectrophoresis or immunofixation RYO 71061

Cryptococcal antigen—microbial antigen testingCRYN 69219

Cryptococcus—microbial antibody testing CRY 69229

CSF—microscopy and culture of material from MCS3 69209

CSF antigens—group B streptococcus STB 69219

CSF antigens—Haemophilus influenzae HI 69219

CSF antigens—Neisseria meningitidis NMG 69219

CSF antigens—Streptoccus pneumoniae SPN 69219

Cultural examination of faeces FCS 69211

Cyclic AMP CAMP 66405

Cyclosporin A CLSA 66235

Cystine—qualitative UCYS 66213

Cystine—quantitative CYST 66367

Cytology—from body fluids, sputum (1 specimen), urine, washings or brushings BFCY 73045

Cytology—from cervix—routine CCR 73053

Cytology—from cervix—abnormalities CCRA 73055

Cytology—from fine needle aspiration of solid tissuesFNCY 73049

Cytology—from fine needle aspiration of solid tissues—aspiration or attendance by a pathologist FNCP 73051

Cytology—from skin, nipple discharge, lip, mouth, nose or anusSMCY 73043

Cytology—from vagina CVO 73057

Cytology—from 3 sputum or urine specimens SPCY 73047

Cytomegalovirus—microbial antibody testing CMV 69229

Cytomegalovirus serology in pregnancy—microbial antibody testingCMVP 69253‑57

D‑dimer test DD 65029

D vitamin VITD 66271

Dehydroepiandrosterone sulphate (DHEAS) DHEA 66405

Dengue—microbial antibody testing DEN 69229

11-Deoxycortisol DCOR 66405

Desipramine DESI 66235

Dexamethasone DXST 66295

Dexamethasone—suppression test DEXA 66295

DHEAS (Dehydroepiandrosterone sulphate) DHEA 66405

Diazepam DIAZ 66235

Differential cell count DIFF 65005

Digoxin DIG 66235

Dihydrotesterone DHTS 66405

Diphenylhydantoin (Dilantin) DIL 66235

Diphtheria—microbial antibody testing DIP 69229

Direct Coombs test CMBS 65005,

65027

Disopyramide (Rythmodan) DISO 66235

DNA, double‑stranded antibodies DNAD 71099

DNA binding—quantitation and measurement if positive ANAANAP 71099

Down's syndrome and neural tube defects NTDD 66321

Doxepin hydrochloride DOXE 66235

Drugs—abuse treatment programme—assay DATP 66343

Drugs—inappropriate dosage—assay DRGO 66231

Drugs—therapeutic—assay (see individual drugs)

Dynamic function tests GHSE 66295

Ear—microscopy and culture of material from MCS1 69205

Echinococcus—microbial antibody testing ECC 69229

Echo‑coxsackie group—microbial antibody testing ECH 69229

Electrolytes (see group tests in Division A)

Electron microscopy of biopsy material EM 72807

Electrophoresis, to demonstrate—creatine kinase isoenzymes CKIE 66249

Electrophoresis, to demonstrate—lactate dehydrogenase isoenzymesLDI 66249

Electrophoresis, to demonstrate—lipoprotein subclasses LEPG 66250

Electrophoresis, to demonstrate—protein classes, or paraproteinEPP1 66249

Electrophoresis, to demonstrate—protein classes or presence and amount of paraprotein classes, concurrent collection EPP2 66247

Elements (see individual elements)

Entamoeba histolytica—microbial antibody testingAMO 69229

Enzyme assays of solid tissue or tissues ENZS 66285

Epstein Barr virus—microbial antibody testing EBV 69229

Erythrocyte—assessment of haemolysis ERYH 65009

Erythrocyte—assessment of metabolic enzymesERYM 65009

Erythrocyte—count RCC 65001

Erythrocyte—sedimentation rate ESR 65001

Ethosuximide (Zarontin) ETHO 66235

Euglobulin clot lysis time ECLT 65037

Extractable nuclear antigens—detection of antibodies to ENA 71101

Eye—microscopy and culture of material from MCS1 69205

Factor II FII 65045

Factor V FV 65045

Factor VII FVII 65045

Factor VIII VIII 65045

Factor IX FIX 65045

Factor X FX 65045

Factor XI FXI 65045

Factor XII FXII 65045

Factor XIII XIII 65045

Factor XIII deficiency test F13D 65029

Faecal blood FOB 66221

Faecal fat FFAT 66283

Faecal fat—haemoglobin—chemical test FHC 66217

Faecal fat—haemoglobin—immunological test FHI 66219

Faecal fat—porphyrins—qualitative test FPR 66217

Faecal fat—reducing substances FRS 66217

Faeces—culture FCS 69211

Faeces—microscopy for parasites OCP 69203

Fatty acids—total free—quantitation TFFA 66367

Ferritin (see also Iron studies) FERR 66355

Fibrin monomer FM 65029

Fibrinogen FIB 65029

Fibrinogen—degradation products FDP 65029

Fitzgerald factor FGF 65045

Flecainide FLEC 66235

Fletcher factor FF 65045

Fluorescent treponemal antibody—absorption test (FTA‑ABS)—microbial antibody testing FTA 69229

Fluoxetine FLUX 66235

Folate—red cell RCF 66267

Follicle stimulating hormone (FSH) FSH 66405

Frozen section diagnosis of biopsy material FS 72803

Fructosamine FRUC 66201

Full blood examination FBE 65007

Gamma glutamyl transpeptidase GGT 66201

Gastric parietal cell—tissue antigens—antibodies PCA 71119

Gastrin GAST 66405

Gliadin IgA—tissue antigens—antibodies GLIA 71119

Globulin GLOB 66201

Glomerular basement membrane—tissue antigens—antibodies GBA 71109

Glucagon GLGO 66405

Glucagon stimulation test GSTC 66297

Glucose GLUC 66201

Glucose—tolerance test GTT 66419

Glycolated haemoglobin (Hb A1c) GHB 66319

Glycosylated haemoglobin (Hb A1c) GHB 66319

Gold AU 66277

Gonadotrophin GRHS 66297

Group B streptococcus—CSF antigens STB 69219

Group B streptococcus—microbial antigen testingSTB 69219

Group P9—simple basic pathology tests 73801‑11

Growth hormone GH 66405

Growth hormone—stimulation by exercise or L‑dopa GHSE 66295

Growth hormone—suppression by dexamethasone or glucose GHSG 66295

Haematocrit HCT 65001

Haemoglobin HB 65001

Haemoglobin—in urine UHB 66213

Haemoglobinopathy tests HMGP 65011

Haemophilus influenzae antigens HI 69219

Haemophilus influenzae—microbial antibody testingHUS 69229

Haemophilus influenzae—microbial antigen testing HI 69219

Haloperidol HALO 66235

Haptoglobins HGLB 66361

HDL cholesterol HDLC 66317

Heart—tissue antigens—antibodies AHE 71109

Heparin—cofactor II HRNC 65037

Heparin—test HEPR 65043

Hepatitis delta antibody—anti‑delta—microbial antibody testing HDA 69229

Hepatitis serology—acute hepatitis HEP 69247

Hepatitis serology—follow‑up of proven hepatitis B HEPB 69249

Hepatitis serology—hepatitis B serology to define immune statusHEP1 69245

Hepatitis serology—hepatitis B surface antigen HBsAg HBSA 69243

Hepatitis serology—hepatitis C HEPC 69265

Hepatitis serology—hepatitis delta antibody HDA 69229

Hepatitis serology—in pregnancy HEPP 69253‑57

Herpes simplex virus—direct detection from clinical material HSV 69223

Herpes simplex virus—investigation by culture HSVC 69263

Herpes simplex virus—microbial antibody testingHPA 69229

Herpes simplex virus—microbial antigen testing HSV 69223

Heterophile antibodies IM 65005,

65027

HIAA (hydroxyindoleacetic acid) HIAA 66367

Histamine HIAM 66367

Histone—tissue antigens—antibodies AHI 71109

Histopathology of biopsy material HIST 72801

Histoplasma—microbial antibody testing HIP 69229

HLA typing—HLA‑B27 HLAB 71147

HLA typing—HLA class 1 HLA1 71149

HLA typing—HLA class 2 HLA2 71151

HMMA (hydroxy‑3‑methoxymandelic acid, previously known as VMA)HMMA 66281

HMPG (hydroxy-methoxy-phenylethylene glycol)HMPG 66281

Homovanillic acid HVA 66281

Hormone receptor assay—breast HRA 66315

Hormone receptor assay—ovary HRO 66315

Hormones—adrenocorticotrophic ACTH 66405

Hormones—aldosterone ALDS 66405

Hormones—androstanedione ANDR 66405

Hormones—C‑Peptide CPEP 66405

Hormones—calcitonin CALT 66405

Hormones—cortisol CORT 66405

Hormones—cyclic AMP CAMP 66405

Hormones—dehydroepiandrosterone sulphate (DHEAS) DHEA 66405

Hormones—dihydrotestosterone DHTS 66405

Hormones—follicle stimulating hormone FSH 66405

Hormones—gastrin GAST 66405

Hormones—glucagon GLGO 66405

Hormones—gonadotrophin GRHS 66297

Hormones—growth hormone GH 66405

Hormones—growth hormone—stimulation by exercise or L‑dopa GHSE 66295

Hormones—growth hormone—suppression by dexamethasone or glucose GHSG 66295

Hormones—hormone receptor assay—breast HRA 66315

Hormones—hormone receptor assay—ovary HRO 66315

Hormones—human chorionic gonadotrophin—for pregnancy diagnosis HCG 73527

Hormones—human chorionic gonadotrophin (see human chorionic gonadotrophin)

Hormones—human placental lactogen HPL 66373

Hormones—hydroxyprogesterone OHP 66405

Hormones—insulin INS 66405

Hormones—insulin, hypoglycaemia test INHY 66297

Hormones—luteinising hormone LH 66405

Hormones—oestradiol E2 66405

Hormones—oestriol E3 66373

Hormones—oestrone E1 66405

Hormones—parathyroid hormone PTH 66405

Hormones—pentagastrin PSTR 66297

Hormones—progesterone PROG 66405

Hormones—prolactin PROL 66405

Hormones—renin REN 66405

Hormones—sex hormone binding globulin SHBG 66405

Hormones—somatomedin SOMA 66405

Hormones—testosterone TES 66405

Hormones—urine steroid fraction or fractions USF 66405

Hormones—vasoactive intestinal peptide VIP 66405

Hormones—vasopressin ADH 66405

Hormones—11 deoxycortisol DCOR 66405

Hormones and hormone binding proteins (see individual hormones and proteins) 66405

Huhner’s test HT 73521

Human chorionic gonadotrophin—for pregnancy diagnosis HCG 73527

Human chorionic gonadotrophin—for diagnosis of specified conditions HCGD 73529

Human chorionic gonadotrophin—for Down's syndrome and neural tube defect testing NTDD 66321

Human placental lactogen HPL 66373

HVA (homovanillic acid) HVA 66281

Hydatid—microbial antibody testing HYD 69229

Hydroxy methoxy phenylethylene glycol HMPG 66281

Hydroxy‑3‑methoxymandelic acid, previously known as VMA) HMMA 66281

Hydroxychloroquine HOCQ 66235

Hydroxyindoleacetic acid HIAA 66367

Hydroxyprogesterone OHP 66405

Hydroxyproline HYDP 66367

Imipramine IMIP 66235

Immediate frozen-section diagnosis of biopsy materialFS 72803

Immunoglobulins—A IGA 71067

Immunoglobulins—D IGD 71067

Immunoglobulins—E (total) IGE 71075‑79

Immunoglobulins—G IGG 71067

Immunoglobulins—G, 4 subclasses SIGG 71073

Immunoglobulins—M IGM 71067

Immunohistochemical investigation of biopsy material HIS 72805

Infectious mononucleosis IM 69229

Influenza A—microbial antibody testing FLA 69229

Influenza B—microbial antibody testing FLB 69229

Insulin INS 66405

Insulin—hypoglycaemia test INHY 66297

Insulin—tissue antigens—antibodies AINS 71109

Insulin receptor antibodies—tissue antigens—antibodies INSA 71109

Intercellular cement substance of skin—tissue antigens—antibodiesICCS 71109

Intestinal disaccharidases INTD 66283

Intrinsic factor—tissue antigens—antibodies AIF 71109

Iron studies (iron, transferrin and ferritin) IS 66263

Islet cell—tissue antigens—antibodies AIC 71109

Jo‑1—tissue antigens—antibodies JO1 71119

Keratin—tissue antigens—antibodies KERA 71119

L‑dopa GHLD 66295

Lactate LACT 66367

Lactate—dehydrogenase LDH 66201

Lactate—dehydrogenase isoenzymes LDI 66249

Lamellar body phospholipid LBPH 66243

Lead PB 66279

Lecithin/sphingomyelin ratio (amniotic fluid) LS 66243

Legionella pneumophila—serogroup 1—microbial antibody testingLP1 69229

Legionella pneumophila—serogroup 2—microbial antibody testingLP2 69229

Leishmaniasis—microbial antibody testing LEI 69229

Leptospira—microbial antibody testing LEP 69229

Leucocyte count WCC 65001

Leucocyte—3 surface markers—blood, CSF, serous fluid LMH3 71139

Leucocyte—3 surface markers—tissue LMT3 71141

Leucocyte—6 surface markers—blood, CSF, serous fluid or tissueLM6 71143

Leucocyte—6 surface markers—blood, CSF, serous fluid and tissue (s) LMHT 71145

Lignocaine LIGN 66235

Lip—cytology on specimens from SMCY 73043

Lipase LIP 66201

Lipid studies (see group tests in Division A)

Lipoprotein electrophoresis LEPG 66250

Listeria—microbial antibody testing LIS 69229

Lithium LI 66201

Liver function tests (see group tests) LFT 66211

Liver/kidney microsomes—tissue antigens—antibodies LKA 71119

Lupus anticoagulant LUPA 65037

Luteinising hormone LH 66405

Lymphocyte—tissue antigens—antibodies ALY 71109

Lymphocytes—functional tests—1 test LF1 71127

Lymphocytes—functional tests—2 tests LF2 71129

Lymphocytes—functional tests—3 tests LF3 71131

Magnesium MG 66201

Mammary serum antigen MSA 66261

Manganese MN 66277

Mantoux test MANT 73811

Measles—microbial antibody testing MEA 69229

Melanogen (see Urine melanin)

Mercury HG 66277

Metalbumin detection (Schumm’s test) SCHM 65027

Metanephrines MNEP 66281

Methadone MTDN 66235

Methotrexate MTTA 66235

Methsuximide MSUX 66235

Metronidazole MRDZ 66235

Mexiletine (Mexitil) MEX 66235

Mianserin MIAS 66235

Microalbumin MALB 66361

Microbial antibody testing—actinomycetes ACT 69229

Microbial antibody testing—adenovirus ADE 69229

Microbial antibody testing—aspergillus ASP 69229

Microbial antibody testing—avian precipitins (see avian precipitions)

Microbial antibody testing—Blastomyces BLM 69229

Microbial antibody testing—Bordetella pertussis BOR 69229

Microbial antibody testing—Borrelia burgdorferi BOB 69229

Microbial antibody testing—Brucella BRU 69229

Microbial antibody testing—Campylobacter jejuniCAM 69229

Microbial antibody testing—Candida CAN 69229

Microbial antibody testing—Chlamydia CHL 69229

Microbial antibody testing—Coccidioides CCC 69229

Microbial antibody testing—Coxsackie B1‑6COX 69229

Microbial antibody testing—cryptococcus CRY 69229

Microbial antibody testing—cytomegalovirus CMV 69229

Microbial antibody testing—cytomegalovirus serology in pregnancyCMVP 69253‑57

Microbial antibody testing—dengue DEN 69229

Microbial antibody testing—diphtheria DIP 69229

Microbial antibody testing—echinococcus ECC 69299

Microbial antibody testing—echo‑coxsackie group ECH 69229

Microbial antibody testing—Entamoeba histolyticaAMO 69229

Microbial antibody testing—Epstein Barr virus EBV 69229

Microbial antibody testing—fluorescent treponemal antibody—absorption test (FTA‑ABS) FTA 69229

Microbial antibody testing—Haemophilus influenzaeHUS 69229

Microbial antibody testing—hepatitis C HEPC 69265

Microbial antibody testing—hepatitis delta antibody—anti‑delta HDA 69229

Microbial antibody testing—herpes HPA 69229

Microbial antibody testing—Histoplasma HIP 69229

Microbial antibody testing—hydatid HYD 69229

Microbial antibody testing—infectious mononucleosisIM 69229

Microbial antibody testing—influenza A FLA 69229

Microbial antibody testing—influenza B FLB 69229

Microbial antibody testing—Legionella pneumophila—serogroup 1LP1 69229

Microbial antibody testing—Legionella pneumophila—serogroup 2LP2 69229

Microbial antibody testing—leishmaniasis LEI 69229

Microbial antibody testing—Leptospira LEP 69229

Microbial antibody testing—Listeria LIS 69229

Microbial antibody testing—measles MEA 69229

Microbial antibody testing—Micropolyspora faeniMIC 69229

Microbial antibody testing—mumps MUM 69229

Microbial antibody testing—Murray Valley encephalitis MVE 69229

Microbial antibody testing—Mycoplasma pneumoniae MYC 69229

Microbial antibody testing—Neisseria menigitidisMEN 69229

Microbial antibody testing—Newcastle disease NCD 69229

Microbial antibody testing—parainfluenza 1 PF1 69229

Microbial antibody testing—parainfluenza 2 PF2 69229

Microbial antibody testing—parainfluenza 3 PF3 69229

Microbial antibody testing—paratyphi PTY 69229

Microbial antibody testing—pertussis PER 69229

Microbial antibody testing—poliomyelitis PLO 69229

Microbial antibody testing—Proteus OX 19 POX 69229

Microbial antibody testing—Proteus OXK POK 69229

Microbial antibody testing—Q fever QFF 69229

Microbial antibody testing—rapid plasma reagin testRPR 69229

Microbial antibody testing—respiratory syncytial virus RSV 69229

Microbial antibody testing—Ross River virus RRV 69229

Microbial antibody testing—rubella RUB 69229

Microbial antibody testing—Salmonella typhi (H)SAH 69229

Microbial antibody testing—Salmonella typhi (O)SAO 69229

Microbial antibody testing—Schistosoma STO 69229

Microbial antibody testing—streptococcal serology—anti‑DNASE B titre ADNB 69229

Microbial antibody testing—streptococcal serology—anti‑streptolysin O titre ASOT 69229

Microbial antibody testing—Streptococcus pneumoniae PCC 69229

Microbial antibody testing—tetanus TET 69229

Microbial antibody testing—Thermoactinomyces vulgaris THE 69229

Microbial antibody testing—thermopolyspora TPS 69229

Microbial antibody testing—Toxocara TOC 69229

Microbial antibody testing—toxoplasma TOX 69229

Microbial antibody testing—TPHA (Treponema pallidum haemagglutination test) TPHA 69229

Microbial antibody testing—trichinosis TOS 69229

Microbial antibody testing—typhus, Weil‑Felix TYP 69229

Microbial antibody testing—Varicella zoster VCZ 69229

Microbial antibody testing—VDRL (Venereal Disease Research Laboratory) VDRL 69229

Microbial antibody testing—Yersinia enterocoliticaYER 69229

Microbial antigen testing—Chlamydia CHLY 69221

Microbial antigen testing—Clostridium difficileCLDT 69219

Microbial antigen testing—group B streptococcus STB 69219

Microbial antigen testing—Haemophilus influenzaeHI 69219

Microbial antigen testing—herpes simplex virus HSV 69263

Microbial antigen testing—Neisseria gonorrhoeaeGON 69219

Microbial antigen testing—Neisseria meningitidisNMG 69219

Microbial antigen testing—respiratory syncytial virusRSVN 69219

Microbial antigen testing—Streptococcus pneumoniaeSPN 69219

Microbial antigen testing—Varicella zoster VCZN 69219

Micropolyspora faeni MIC 69229

Microscopic examination of—faeces for parasitesOCP 69203

Microscopic examination of—material other than blood M 69201

Microscopy and culture of—material from nose, throat, eye or earMCS1 69205

Microscopy and culture of—material from skin, superficial sites, urethra, vagina, cervix or rectum MCS2 69207

Microscopy and culture of—post‑op wounds, aspirations of body cavities, synovial fluid, CSF and op/biopsy specimens MCS3 69209

Microscopy and culture of—specimens of sputumMCS2 69207

Microscopy and culture of—specimens of sputum, urine or other body fluids for mycobacteriaAFB 69213

Microscopy, culture, identification and sensitivity of urine UMCS 69217

Mitochondria—tissue antigens—antibodies MA 71119

Mouth—cytology on specimens from SMCY 73043

Mucin‑like carcinoma-associated antigenMCA1 66261

Mumps—microbial antibody testing MUM 69229

Murray Valley encephalitis—microbial antibody testing MVE 69229

Mycobacteria microscopy and culture of sputum AFB 69213

Mycoplasma pneumoniae—microbial antibody testingMYC 69229

Myoglobin in urine UMY 66213

N‑acetyl procainamide NAPC 66235

Neisseria gonorrhoeae—microbial antigen testingGON 69219

Neisseria menigitidis antigens NMG 69219

Neisseria menigitidis—microbial antibody testingMEN 69229

Neisseria menigitidis—microbial antigen testing NMG 69219

Neural tube defects and Down's syndrome NTDD 66321

Neuron—tissue antigens—antibodies ANE 71109

Neuron specific enolase NSEN 66261

Neutrophil cytoplasm—tissue antigens—antibodiesANCA 71109

Neutrophil functions NFT 71135

Newcastle disease—microbial antibody testing NCD 69229

Nickel NI 66277

Nipple discharge—cytology on specimens fromSMCY 73043

Nitrazepam NITR 66235

Nordothiepin NDIP 66235

Norfluoxetine NFLE 66235

Nortriptyline NORT 66235

Nose—cytology on specimens from SMCY 73043

Nose—microscopy and culture of material MCS1 69205

Nuclear antigens—detection of antibodies to ANA 71097

Oestradiol E2 66405

Oestriol E3 66373

Oestriol—for Down's syndrome and neural tube defect testing NTDD 66321

Oestrone E1 66405

Oligoclonal proteins OGP 71065

Op/biopsy specimens—microscopy and culture of material fromMCS3 69209

Osmolality—serum or urine OSML 66223

Ovary—tissue antigens—antibodies AOV 71109

Oxalate OXAL 66367

Oxazepam OXAZ 66235

PAA (phenyl acetic acid) PAA 66281

Palmitic acid in amniotic fluid PALM 66243

Pap smear CCR 73053

Papanicolaou test CCR 73053

Paracetamol PARA 66235

Parainfluenza 1—microbial antibody testing PF1 69229

Parainfluenza 2—microbial antibody testing PF2 69229

Parainfluenza 3—microbial antibody testing PF3 69229

Paraprotein investigation—by electrophoresis EPPI 66249

Paraprotein investigation—by immunoelectrophoresis or immunofixation PPRO 71061

Paraprotein investigation—on concurrently collected serum or urinePPSU 71063

Paraquat PARQ 66235

Parasites—microscopic examination of faeces OCP 69203

Parathyroid hormone (PTH) PTH 66405

Parathyroid—tissue antigens—antibodies PTHA 71109

Paratyphi—microbial antibody testing PTY 69229

Partial thromboplastin time PTT 65029

Passovy factor PF 65045

Patient episode initiation PEI 73901‑15

Pentagastrin PSTR 66297

Pentobarbitone PENT 66235

Perhexiline PHEX 66235

Pertussis—microbial antibody testing PER 69229

pH measurement of body fluids other than urine PH 66213

Phenobarbitone PHBA 66235

Phensuximide PHEN 66235

Phenylacetic acid PAA 66281

Phenytoin PHEY 66235

Phosphate PHOS 66201

Phosphatidylglycerol PTGL 66243

Plasminogen PLAS 65037

Platelet—aggregation PLTG 65041

Platelet—count PLTC 65001

Platelet—tissue antigens—antibodies APA 71109

PM‑Sc1—tissue antigens—antibodies PM1 71119

Poliomyelitis—microbial antibody testing PLO 69229

Porphobilingen in urine UPG 66213

Porphyrins—quantitative test, 1 or more fractions PR 66281

Porphyrins in urine—qualitative test UPR 66213

Potassium K 66201

Prealbumin PALB 66361

Prednisolone PRED 66235

Pregnancy serology—1 test MSP1 69253

Pregnancy serology—2 tests MSP2 69255

Pregnancy serology—3 tests MSP3 69257

Pregnancy testing 73805

Pregnancy testing—diagnosis HCG 73527

Pregnancy testing—diagnosis of specified conditionsHCGD 73529

Pregnancy testing—for diagnosis of Down's syndrome and neural tube defect NTDD 66321

Primidone PRIM 66235

Procainamide PCAM 66235

Progesterone PROG 66405

Prolactin PROL 66405

Prominal PROM 66235

Propranolol PPNO 66235

Prostate specific antigen PSA 66357

Prostatic acid phosphatase ACP 66357

Protein—C PROC 65037

Protein—S PROS 65037

Protein, quantitation of—alpha fetoprotein AFP 66353

Protein, quantitation of—alpha fetoprotein—for Down's syndrome and neural tube defect testing NTDD 66321

Protein, quantitation of—alpha‑l‑antitrypsin AAT 66255

Protein, quantitation of—alpha‑2‑macroglobulinAMAC 66255

Protein, quantitation of—beta‑2‑microglobulinBMIC 66361

Protein, quantitation of—C‑l esterase inhibitor CEI 66257

Protein, quantitation of—caeruloplasmin CPLS 66361

Protein, quantitation of—classes by electrophoresisEPPI 66249

Protein, quantitation of—ferritin (see also Iron studies) FERR 66355

Protein, quantitation of—haptoglobins HGLB 66361

Protein, quantitation of—microalbumin MALB 66361

Protein, total—quantitation of PROT 66201

Proteus OX 19—microbial antibody testing POX 69229

Proteus OXK—microbial antibody testing POK 69229

Prothrombin time PT 65029

Pyruvate PVTE 66367

Q fever—microbial antibody testing QFF 69229

Quinalbarb QUIB 66235

Quinidine QUIN 66235

Quinine QNN 66235

Rapid plasma reagin test—microbial antibody testingRPR 69229

RAST RAST 71079

Rectum—microscopy and culture of material fromMCS2 69207

Red cell folate and serum B12 and serum folate if required RCF 66267

Red cell porphyrins—qualitative test RCP 65027

Referred specimen fee 73921

Renin REN 66405

Respiratory syncytial virus—microbial antibody testing RSV 69229

Respiratory syncytial virus—microbial antigen testingRSVN 69219

Reticulin—tissue antigens—antibodies RCA 71119

Reticulocyte count RETC 65001

Rheumatoid factor RF 71106

Rheumatoid factor—quantitation RFQ 71106

Ross River virus—microbial antibody testing RRV 69229

RSV (respiratory syncytial virus)—microbial antigen testing RSVN 69219

RSV (respiratory syncytial virus)—microbial antibody testing RSV 69229

Rubella—serology RUB 69229

Salicylate—aspirin SALI 66235

Salivary gland—tissue antigens—antibodies ASG 71109

Salmonella typhi (H)—microbial antibody testingSAH 69229

Salmonella typhi (O)—microbial antibody testingSAO 69229

Schistosoma—microbial antibody testing STO 69229

Scl‑70—tissue antigens—antibodies SCL 71119

Secretin SSGR 66297

Selenium SE 66277

Semen examination SEE 73523

Semen examination—for spermatozoa (post vasectomy) SES 73521

Serology—in pregnancy (see Pregnancy serology)

Serotonin 5HT 66367

Serum—Bl2 B12 66265

Serum—folate (with Bl2) FOL 66265

Serum—folate (with Bl2 red cell folate) RCF 66267

Sex hormone binding globulin SHBG 66405

Skeletal muscle—tissue antigens—antibodies SLA 71109

Skin—cytology SMCY 73043

Skin—microscopy and culture of material from MCS2 69207

Skin basement membrane—tissue antigens—antibodies SKA 71109

Snake venom HISS 66231

Smooth muscle—tissue antigens—antibodies SMA 71119

Sodium NA 66201

Solid tissue or tissues—chemical assays ENZS 66285

Solid tissue or tissues—cytology of fine needle aspiration FNCY 73049

Solid tissue or tissues—cytology of fine needle aspiration by, or in presence of, pathologistFNCP 73051

Somatomedin SOMA 66405

Sotalol SALL 66235

Specific IgG or IgE antibodies RAST 71079

Specimen referred fee 73921

Sperm antibodies SAB 73525

Sperm antibodies—penetrating ability SPA 73525

Sputum—cytology (1 specimen) BFCY 73045

Sputum—cytology (3 specimens) SPCY 73047

Sputum—microscopy and culture of specimens MCS2 69207

Sputum—for mycobacteria AFB 69213

Stelazine STEL 66235

Steroid fraction or fractions in urine USF 66405

Streptococcal serology—anti‑DNASE B titre—microbial antibody testing ADNB 69229

Streptococcal serology—anti‑streptolysin O titre—microbial antibody testing ASOT 69229

Streptococcus—Group B STB 69219

Streptococcus pneumoniae—antigens SPN 69219

Streptococcus pneumoniae—microbial antibody testing PCC 69229

Streptococcus pneumoniae—microbial antigen testingSPN 69219

Strontium SR 66277

Sulthiame (Ospolot) SUL 66235

Synacthen stimulation test SYNS 66297

Syphilis serology (see group tests) STS 69231

Testosterone TES 66405

Tetanus—microbial antibody testing TET 69229

Thalassaemia studies TS 65011

Theophylline THEO 66235

Thermoactinomyces vulgaris—microbial antibody testing THE 69229

Thermopolyspora—microbial antibody testing TPS 69229

Thiopentone TOPO 66235

Thioridazine THIO 66235

Throat—microscopy and culture of material fromMCS1 69205

Thrombin time TT 65029

Thyroglobulin TGL 66261

Thyroglobulin—tissue antigens—antibodies ATG 71109

Thyroid function tests (including TSH) TFT 66329

Thyroid stimulating hormone (if requested on its own, or as a preliminary test to thyroid function testing) TSH 66327

Thyroid stimulating hormone (if requested with other hormones referred to in item 66405)) TSH 66405

Thyroid microsome—tissue antigens—antibodiesTMA 71109

Thyrotrophin releasing hormone test TRH 66293

Total free fatty acids TFFA 66367

Total protein PROT 66201

Toxocara—microbial antibody testing TOC 69229

Toxoplasma—microbial antibody testing TOX 69229

TPHA (Treponema pallidum haemagglutination test)—microbial antibody testing TPHA 69229

Treponema pallidum haemagglutination test—microbial antibody testing TPHA 69229

Trichinosis—microbial antibody testing TOS 69229

Triglycerides TRIG 66331

Trimipramine TRIM 66235

Tryptic activity in faeces TAF 66323

TSH receptor antibody test—tissue antigens—antibodies TSHA 71109

Tuberculosis MANT 73811

Tumour markers—CA‑15.3 antigen CA15 66261

Tumour markers—CA‑19.9 antigen CA19 66261

Tumour markers—CA‑125 antigen C125 66261

Tumour markers—carcinoembryonic antigen CEA 66261

Tumour markers—mammary serum antigen MSA 66261

Tumour markers—mucin‑like carcinoma associated antigenMCA 66261

Tumour markers—neuron specific enolase NSEN 66261

Tumour markers—prostate specific antigen PSA 66357

Tumour markers—prostatic acid phosphatase‑1 or more fractions ACP 66357

Tumour markers—thyroglobulin TGL 66261

Typhus, Weil‑Felix—microbial antibody testing TYP 69229

Urate URAT 66201

Urea U 66201

Urea, electrolytes, creatinine (see group tests in Division A)

Urethra—microscopy and culture of material fromMCS2 69207

Urine—bilirubin UBIL 66213

Urine—catalase test 73805

Urine—cytology—on 1 specimen BFCY 73045

Urine—cytology—on 3 specimens SPCY 73047

Urine—cystine (cysteine) UCYS 66213

Urine—haemoglobin UHB 66213

Urine—melanin (melanogen) UML 66213

Urine—microscopy, culture, identification and sensitivity UMCS 69217

Urine—myoglobin UMY 66213

Urine—porphobilinogen UPG 66213

Urine—porphyrins—qualitative test UPR 66213

Urine—steroid fraction or fractions USF 66405

Urine—urobilinogen UUB 66213

Vagina—cytology on specimens from CVO 73057

Vagina—microscopy and culture of material fromMCS2 69207

Valproate (Epilim) VALP 66235

Vancomycin VAN 66235

Varicella zoster—microbial antibody testing VCZ 69229

Varicella zoster—microbial antigen testing VCZN 69219

Vasoactive intestinal peptide VIP 66405

Vasopressin ADH 66405

VDRL (Venereal Disease Research Laboratory)—microbial antibody testing VDRL 69229

Viscosity of blood or plasma VISC 65001

Vitamins—B12 RCF 66267

Vitamins—D VITD 66271

Vitamins—folate RCF 66267

Vitamins—quantitation of A, B1, B2, B3, B6, C or EVIT 66269

VMA (see HMMA)

Von Willebrand’s factor VWF 65045

Von Willebrand’s factor antigen VWA 65045

Warfarin WFR 66235

Xylose XYL 66367

Yersinia enterocolitica—microbial antibody testingYER 69229

Zinc ZN 66367

NOTE

1. Notified in the Commonwealth of Australia Gazette on 28 September 1995.

Group	Tests included in group	Abbreviation	Item numbers
Cardiac enzymes	Lactate dehydrogenase (LDH), aspartate aminotransferase (AST) and creatine kinase (CK)	CE	66205
Coagulation studies	Prothrombin time, activated partial thrombo-plastin time and two or more of the following tests—bleeding time, thrombin clotting time, fibrinogen degradation products, fibrin monomer, D-dimer, factor XIII screening tests	COAG	65035
Electrolytes	Sodium (NA), potassium (K), chloride (Cl), and bicarbonate (HCO3)	E	66207
Lipid studies	Cholesterol (CHOL) and triglycerides (TRIG)	FATS	66331
Liver function tests	Alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin (ALB), bilirubin (BIL), gamma glutamyl transpeptidase (GGT), lactate dehydrogenase (LDH), and protein (PROT)	LFT	66211